CRRT的规范化治疗.pptVIP

CRRT的规范化治疗

;概述;CRRT;历史;主要技术;2021/3/29星期一;2021/3/29星期一;2021/3/29星期一;2021/3/29星期一;2021/3/29星期一;2021/3/29星期一;总结;急性肾损伤;RIFLECriteriaforAcuteRenalDysfunction;“AcuteonChronic”Disease;AKIN分层标准;适应症;肾脏疾病;Acuterenalfailure;非肾脏疾病;禁忌症;PotentialindicationsforCRRTintheICU;PotentialindicationsforCRRTintheICU;治疗前患者评估;CRRT现状调查;CRRT现状调查;Age(years)66(51–74)ReasonstostartCRRT

Gender(male)662/1006(65.8%)Oliguria/anuria703/1002(70.2%)

PremorbidrenalfunctionHighurea/creatinine531/1002(53.0%)

Normal590/1006(58.6%)Metabolicacidosis437/1002(43.6%)

Chronicimpairment283/1006(28.1%)Fluidoverload368/1002(36.7%)

Unknown133/1006(13.2%)Hyperkalemia186/1002(18.6%)

SAPSII48(39–62)Immunomodulation136/1002(13.6%)

Predictedmortality(%)41.5(23.0–71.4)Others70/1002(7.0%)

HospitaltoICU(days)1(0–7)ICUmortality555/1003(55.3%)

ICUtostart(days)1.2(0.4–4.1)Hospitalmortality641/999(64.2%)

ContributingfactorstoARFSMR1.38(1.28–1.50)

Sepsis/septicshock504/1003(50.2%)

Majorsurgery377/1003(37.6%)

Lowcardiacoutput262/1003(26.1%)

Hypovolemia201/1003(20.0%)

Druginduced176/1003(17.5%)

Hepatorenalsyndrome73/1003(7.3%)

Obstructiveuropathy20/1003(2.0%)

Others114/1003(11.4%);CRRTmodeAnticoagulation

CVVH531/1006(52.8%)Unfractionatedheparin429/1000(42.9%)

CVVHDF342/1006(34.0%)So